Immunome, Inc. Common Stock Earnings Dividend

Immunome, Inc. Common Stock’s revenue fell -100% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Immunome, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.

Immunome, Inc. Common Stock’s net profit fell -68.51% since last year same period to $-73.13Mn in the Q2 2026. On a quarterly growth basis, Immunome, Inc. Common Stock has generated -35.83% fall in its net profits since last 3-months.

Immunome, Inc. Common Stock’s net profit margin fell -Inf% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Immunome, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.

Immunome, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.64 - a -25.49% fall from last quarter’s estimates.

Immunome, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.64.

Immunome, Inc. Common Stock’s earning per share (EPS) fell -30% since last year same period to -0.65 in the Q2 2026. This indicates that the Immunome, Inc. Common Stock has generated -30% annual rate of fall in its earning per share (EPS) in the last 4 quarters.